Potentials of cellulosic wastes in media formulation

Potential use of cellulosic wastes as carbon and energy sources in selective media formulations was investigated. Two agar media, Czapek-Dox and Sabouraud’s agar, were modified by substituting their carbon sources with cellulose, sawdust and sugarcane pulps. Then, two fungi; Aspergillus niger ANL301 and Penicillium chrysogenum PCL501, newly isolated from wood-wastes, were transferred to the unmodified and modified media and their growth was monitored for 120 h. Growth of the organisms on modified media containing sawdust and sugarcane pulp compared favorably with that obtained for the unmodified equivalents. Modified Czapek-Dox agar containing 2% (w/v) sawdust (Wood agar) and sugarcane pulps (Cane agar) gave 78.9 – 93.3% of the maximum growth obtained on Sabouraud’s agar. The modified Sabouraud’s agar containing sawdust (Wood-Pep agar) and sugarcane pulps (Cane-Pep agar) yielded 84.4 – 100% of the maximum growth on Sabouraud’s agar. Cellulose-containing media gave a lower level of growth (60.0 – 66.7%) of that obtained for the unmodified media

EVALUATION OF OPEN POLLINATED MAIZE VARIETIES FOR RESISTANCE/TOLERANCE TO Striga hermonthica Del. Benth AT MOKWA SOUTHERN GUINEA SAVANNAH OF NIGERIA

Three trials were conducted on the College of Agriculture experimental field which was highly anduniformly infested by Striga at Mokwa (latitude 09o 18'N and longitude 05o 04'E) in the SouthernGuinea Savanna agro- ecological zone of Nigeria during 2004, 2005 and 2006 wet seasons. The studywas conducted to evaluate fifteen maize genotypes consisting of eleven improved, open- pollinatedStriga tolerant varieties, a susceptible 8338-1 and tolerant hybrids 9022-13, an improved recommendedopen pollinated variety and a local selection (Mokwa Dzurugi) for their reaction to Striga hermonthica.The treatments were laid out in a randomized complete block design and replicated fourtimes. Among the varieties tested, TZL Comp.1Syn Y-1F2, Cam, 1 STR – 1 and hybrid 9022-13 consistentlyresulted in significantly lower Striga emergence and crop syndrome reaction to Striga parasitismcompared to all the other varieties including STR genotypes in 2004 and 2005 and of very lowvalues of the parameters in 2006. The varieties also gave higher grain yield comparable to most oftolerant varieties evaluated. Under Striga infestation, maize grain yields of var. TZL Comp. 1 Syn Y-1F2 were 2.94, 3.04 and 2.93 times than those of the recommended TZB- STR (1015kg/ha, 989kg/haand 993kg/ha) in 2004, 2005 and 2006, respectively. The corresponding values for the other promisingvariety, Cam- 1STR-1 were 2.93, 3.05 and 2.89 times higher than TZB STR in 2004, 2005 and 2006respectively. The local selection, Mokwa Dzurugi also exhibited good performance with respect toStriga and maize parameters and could therefore be used in the breeding programme for Striga resistance

Food Insecurity: Challenges of Agricultural Extension in Developing Countries

The emphasis on accelerated agricultural development by developing countries was meant to achieve food security. However, food insecurity has remained a problem throughout much of the developing world and is the result of such factors as slow (as well as highly variable) growth in domestic food production, rapid population growth rates, limited financial capacity to import food and inadequate external assistance. Agricultural extension, on the other hand, plays an important role in development by assuring adequate and timely access by farmers to relevant advice, with appropriate incentives to adopt new technologies if it suits their socio-economic and agroecological circumstances. This paper discusses: the concepts of food security and food insecurity; the causes and consequences of food insecurity; the short-run and long-run measures for alleviating food insecurity; the strengths and weaknesses of some extension modalities; and the modifications to existing extension systems for the achievement of food security. The conclusions drawn are that: (a) improvements in nutritional standards and food security will involve not just a certain rate of agricultural growth, but reduction in population growth rates; and (b) modifications to extension services have the potential to improve agricultural productivity, increase farmers’ incomes, and improve food security

Food Insecurity: Challenges of Agricultural Extension in Developing Countries

The emphasis on accelerated agricultural development by developing countries was meant to achieve food security. However, food insecurity has remained a problem throughout much of the developing world and is the result of such factors as slow (as well as highly variable) growth in domestic food production, rapid population growth rates, limited financial capacity to import food and inadequate external assistance. Agricultural extension, on the other hand, plays an important role in development by assuring adequate and timely access by farmers to relevant advice, with appropriate incentives to adopt new technologies if it suits their socio-economic and agroecological circumstances. This paper discusses: the concepts of food security and food insecurity; the causes and consequences of food insecurity; the short-run and long-run measures for alleviating food insecurity; the strengths and weaknesses of some extension modalities; and the modifications to existing extension systems for the achievement of food security. The conclusions drawn are that: (a) improvements in nutritional standards and food security will involve not just a certain rate of agricultural growth, but reduction in population growth rates; and (b) modifications to extension services have the potential to improve agricultural productivity, increase farmers’ incomes, and improve food security

APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson's disease

The relationship between APOE polymorphisms and Parkinson's disease (PD) in black Africans has not been previously investigated. We evaluated the association between APOE polymorphic variability and self-declared cognition in 1100 Nigerians with PD and 1097 age-matched healthy controls. Cognition in PD was assessed using the single item cognition question (item 1.1) of the MDS-UPDRS. APOE genotype and allele frequencies did not differ between PD and controls (p > 0.05). No allelic or genotypic association was observed between APOE and age at onset of PD. In PD, APOE ε4/ε4 conferred a two-fold risk of cognitive impairment compared to one or no ε4 (HR: 2.09 (95% CI: 1.13-3.89; p = 0.02)), while APOE ε2 was associated with modest protection against cognitive impairment (HR: 0.41 (95% CI 0.19-0.99, p = 0.02)). Of 773 PD with motor phenotype and APOE characterized, tremor-dominant (TD) phenotype predominated significantly in ε2 carriers (87/135, 64.4%) compared to 22.2% in persons with postural instability/gait difficulty (PIGD) (30/135) and 13.3% in indeterminate (ID) (18/135, 13.3%) (p = 0.037). Although the frequency of the TD phenotype was highest in homozygous ε2 carriers (85.7%), the distribution of motor phenotypes across the six genotypes did not differ significantly (p = 0.18). Altogether, our findings support previous studies in other ethnicities, implying a role for APOE ε4 and ε2 as risk and protective factors, respectively, for cognitive impairment in PD

Stroke in Africa: Profile, progress, prospects and priorities

Funding text 1 R.O.A. is supported by the UK Royal Society/African Academy of Sciences FLAIR Grants FLR/R1/191813 and FCG/R1/ 201034, and a GCRF Networking Grant from the UK Academy of Medical Sciences. R.O.A., M.O.O., B.O. and F.S.S. are also supported by grants U54HG007479 and U01HG010273 from the US National Institutes of Health (NIH) as part of the H3Africa Consortium. M.O.O., B.O., R.O.A. and F.S.S. are further supported by NIH grant R01NS107900. R.N.K.’s research on elderly survivors of stroke has been supported by the Medical Research Council, RCUK Newcastle Centre for Brain Ageing and Vitality (MRC G0500247), Alzheimer’s Research UK, the Dunhill Medical Trust, UK, and the Newcastle National Institute for Health Research Biomedical Research Centre in Ageing and Age-Related Diseases, Newcastle upon Tyne Hospitals National Health Service Foundation Trust. Funding text 2 funds provided by the Wellcome Trust and the NIH. The NIH-funded SIREN study is exploring the genetic architecture of stroke among Indigenous Africans. More than 4,000 case–control pairs have already been recruited to the study and several publications on stroke phenom-ics and preliminary candidate gene analyses have been generated. The SIREN study has also undertaken the first-ever GWAS to unravel the genetic architecture of stroke in Indigenous Africans and the results are eagerly awaited. Stroke neurobanking resources consisting of blood fractions, extracted DNA, neuroimages and databases of clinical information are also being built in Africa and could facilitate data science-driven trans-omics research (including epigenomics, tran-scriptomics, proteomics and metabolomics) as well as the development of precision medicine products such as Afrocentric risk calculators, polygenic risk scores, biomarkers and drug targets23–25,227,307,308. The SIREN neurobiobank comprises a group of constantly monitored ultra-low-temperature (–86 °C) freezers located in Ibadan, Nigeria, constantly powered –20 °C chest freezers located in Ibadan and other recruitment sites, barcode scanners and printers, a laboratory information management system, a secure multi-terabyte server,Stroke is a leading cause of disability, dementia, and death worldwide. Approximately 70% of deaths from stroke and 87% of stroke-related disabilities occur in low-income and middle-income countries. At the turn of the century, the most common diseases in Africa were communicable diseases, whereas non-communicable diseases, including stroke, were considered rare, particularly in sub-Saharan Africa. However, evidence indicates that today, Africa could have up to 2–3-fold greater rates of stroke incidence and higher stroke prevalence than western Europe and the USA. In Africa, data published within the past decade show that stroke has an annual incidence rate of up to 316 per 100,000, a prevalence of up to 1,460 per 100,000, and a 3-year fatality rate greater than 80%. Moreover, many Africans have a stroke within the fourth to sixth decades of life, with serious implications for the individual, their family, and society. This age profile is particularly important as strokes in younger people tend to result in a greater loss of self-worth and socioeconomic productivity than in older individuals. Emerging insights from research into stroke epidemiology, genetics, prevention, care, and outcomes offer great prospects for tackling the growing burden of stroke on the continent. In this article, we review the unique profile of stroke in Africa and summarize current knowledge on stroke epidemiology, genetics, prevention, acute care, rehabilitation, outcomes, cost of care, and awareness. We also discuss knowledge gaps, emerging priorities, and future directions of stroke medicine for the more than 1 billion people who live in Africa. © 2021, Springer Nature Limited.Newcastle National Institute for Health Research Biomedical Research Centre in Ageing and Age-Related Diseases Newcastle upon Tyne Hospitals National Health Service Foundation Trust RCUK Newcastle Centre for Brain Ageing and Vitality Royal Society/African Academy of Sciences: FCG/R1/ 201034,FLR/R1/191813 National Institutes of Health (NIH): R01NS107900 Wellcome Trust (WT) Medical Research Council (MRC): G0500247 Dunhill Medical Trust (DMT) Academy of Medical Sciences: U01HG010273,U54HG007479 Alzheimer’s Research UK (ARUK

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19:a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Background Studies of patients admitted to hospital with COVID-19 have found varying mortality outcomes associated with underlying respiratory conditions and inhaled corticosteroid use. Using data from a national, multicentre, prospective cohort, we aimed to characterise people with COVID-19 admitted to hospital with underlying respiratory disease, assess the level of care received, measure in-hospital mortality, and examine the effect of inhaled corticosteroid use. Methods We analysed data from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study. All patients admitted to hospital with COVID-19 across England, Scotland, and Wales between Jan 17 and Aug 3, 2020, were eligible for inclusion in this analysis. Patients with asthma, chronic pulmonary disease, or both, were identified and stratified by age (<16 years, 16–49 years, and ≥50 years). In-hospital mortality was measured by use of multilevel Cox proportional hazards, adjusting for demographics, comorbidities, and medications (inhaled corticosteroids, short-acting β-agonists [SABAs], and long-acting β-agonists [LABAs]). Patients with asthma who were taking an inhaled corticosteroid plus LABA plus another maintenance asthma medication were considered to have severe asthma. Findings 75 463 patients from 258 participating health-care facilities were included in this analysis: 860 patients younger than 16 years (74 [8·6%] with asthma), 8950 patients aged 16–49 years (1867 [20·9%] with asthma), and 65 653 patients aged 50 years and older (5918 [9·0%] with asthma, 10 266 [15·6%] with chronic pulmonary disease, and 2071 [3·2%] with both asthma and chronic pulmonary disease). Patients with asthma were significantly more likely than those without asthma to receive critical care (patients aged 16–49 years: adjusted odds ratio [OR] 1·20 [95% CI 1·05–1·37]; p=0·0080; patients aged ≥50 years: adjusted OR 1·17 [1·08–1·27]; p<0·0001), and patients aged 50 years and older with chronic pulmonary disease (with or without asthma) were significantly less likely than those without a respiratory condition to receive critical care (adjusted OR 0·66 [0·60–0·72] for those without asthma and 0·74 [0·62–0·87] for those with asthma; p<0·0001 for both). In patients aged 16–49 years, only those with severe asthma had a significant increase in mortality compared to those with no asthma (adjusted hazard ratio [HR] 1·17 [95% CI 0·73–1·86] for those on no asthma therapy, 0·99 [0·61–1·58] for those on SABAs only, 0·94 [0·62–1·43] for those on inhaled corticosteroids only, 1·02 [0·67–1·54] for those on inhaled corticosteroids plus LABAs, and 1·96 [1·25–3·08] for those with severe asthma). Among patients aged 50 years and older, those with chronic pulmonary disease had a significantly increased mortality risk, regardless of inhaled corticosteroid use, compared to patients without an underlying respiratory condition (adjusted HR 1·16 [95% CI 1·12–1·22] for those not on inhaled corticosteroids, and 1·10 [1·04–1·16] for those on inhaled corticosteroids; p<0·0001). Patients aged 50 years and older with severe asthma also had an increased mortality risk compared to those not on asthma therapy (adjusted HR 1·24 [95% CI 1·04–1·49]). In patients aged 50 years and older, inhaled corticosteroid use within 2 weeks of hospital admission was associated with decreased mortality in those with asthma, compared to those without an underlying respiratory condition (adjusted HR 0·86 [95% CI 0·80−0·92]). Interpretation Underlying respiratory conditions are common in patients admitted to hospital with COVID-19. Regardless of the severity of symptoms at admission and comorbidities, patients with asthma were more likely, and those with chronic pulmonary disease less likely, to receive critical care than patients without an underlying respiratory condition. In patients aged 16 years and older, severe asthma was associated with increased mortality compared to non-severe asthma. In patients aged 50 years and older, inhaled corticosteroid use in those with asthma was associated with lower mortality than in patients without an underlying respiratory condition; patients with chronic pulmonary disease had significantly increased mortality compared to those with no underlying respiratory condition, regardless of inhaled corticosteroid use. Our results suggest that the use of inhaled corticosteroids, within 2 weeks of admission, improves survival for patients aged 50 years and older with asthma, but not for those with chronic pulmonary disease